Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
المؤلفون المشاركون
Lania, Andrea Gerardo
Campana, Davide
Di Giacinto, Paola
Rota, Francesca
Rizza, Laura
Zuppi, Paolo
Baldelli, Roberto
Lenzi, Andrea
Isidori, Andrea Maria
المصدر
International Journal of Endocrinology
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-07-02
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
Background.
Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index.
The symptoms associated with carcinoid syndrome and vasoactive intestinal peptide tumors are treated with octreotide acetate.
The PROMID trial assesses the effect of octreotide LAR on the tumor growth in patients with well-differentiated metastatic midgut NETs.
The CLARINET trial evaluates the effects of lanreotide in patients with nonfunctional, well-, or moderately differentiated metastatic enteropancreatic NETs.
Everolimus has been approved for the treatment of advanced pancreatic NETs (pNETs) based on positive PFS effects, obtained in the treated group.
Sunitinib is approved for the treatment of patients with progressive gastrointestinal stromal tumor or intolerance to imatinib, because a randomized study demonstrated that it improves PFS and overall survival in patients with advanced well-differentiated pNETs.
In a phase II trial, pasireotide shows efficacy and tolerability in the treatment of patients with advanced NETs, whose symptoms of carcinoid syndrome were resistant to octreotide LAR.
An open-label, phase II trial assesses the clinical activity of long-acting repeatable pasireotide in treatment-naive patients with metastatic grade 1 or 2 NETs.
Even if the growth of the neoplasm was significantly inhibited, it is still unclear whether its antiproliferative action is greater than that of octreotide and lanreotide.
Because new therapeutic options are needed to counter the natural behavior of neuroendocrine tumors, it would also be useful to have a biochemical marker that can be addressed better in the management of these patients.
Chromogranin A is currently the most useful biomarker to establish diagnosis and has some utility in predicting disease recurrence, outcome, and efficacy of therapy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Di Giacinto, Paola& Rota, Francesca& Rizza, Laura& Campana, Davide& Isidori, Andrea Maria& Lania, Andrea Gerardo…[et al.]. 2018. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. International Journal of Endocrinology،Vol. 2018, no. 2018, pp.1-12.
https://search.emarefa.net/detail/BIM-1172111
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Di Giacinto, Paola…[et al.]. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. International Journal of Endocrinology No. 2018 (2018), pp.1-12.
https://search.emarefa.net/detail/BIM-1172111
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Di Giacinto, Paola& Rota, Francesca& Rizza, Laura& Campana, Davide& Isidori, Andrea Maria& Lania, Andrea Gerardo…[et al.]. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. International Journal of Endocrinology. 2018. Vol. 2018, no. 2018, pp.1-12.
https://search.emarefa.net/detail/BIM-1172111
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1172111
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر